Accordingly, a very recent paper indicated that subtyping of MET expression may be required to identify MET-addicted malignancies in CRC patients who will truly benefit from MET inhibition[95].‬‬‬‬‬‬‬‬. Here, MET is linked to colorectal carcinoma.